This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
AVF2107g was a randomized phase 3 treatment study of Avastin (bevacizumab) in combination with standard chemotherapy for colorectal cancer. The registry identifies the study as completed and lists Genentech, Inc. as the lead industry sponsor.
| Feature | AVF2107g |
|---|---|
| Study acronym | AVF2107g |
| ClinicalTrials.gov identifier | NCT00109070 |
| Phase | Phase 3 |
| Status | Completed |
| Condition | Colorectal Cancer |
| Allocation | Randomized |
| Primary purpose | Treatment |
| Intervention | Avastin (bevacizumab) (drug) |
| Lead sponsor | Genentech, Inc. |
| Sponsor type | Industry |
| Start date | 2000-09 |
| Enrollment | Not reported in the registry record |
2. Clinical Question
The registry describes AVF2107g as a study to evaluate Avastin in combination with standard chemotherapy to treat colorectal cancer. The statistical question implied by the randomized treatment design is whether assignment to the Avastin-containing treatment strategy produces different outcomes from the corresponding comparison strategy defined by the trial protocol.
Population
Patients with colorectal cancer enrolled in the AVF2107g phase 3 treatment study.
Intervention
Avastin (bevacizumab) in combination with standard chemotherapy.
Comparator
The registry record identifies the study as randomized, but does not provide the comparator regimen in the information reported here.
Primary question
Whether the addition of Avastin to standard chemotherapy changes the clinical outcomes measured by the study.
3. Trial Design
Randomization is the central design feature for causal comparison. When treatment assignment is randomized, differences in outcomes between randomized groups can be interpreted in relation to treatment assignment, subject to the trial's conduct, analysis population, missing observations, follow-up, and other design considerations.
The registry record identifies the study as randomized but does not report the allocation ratio, treatment-group sample sizes, blinding, number of study locations, crossover procedures, stratification factors, interim-analysis plan, multiplicity strategy, or missing-data method in the information reported here.
4. Endpoints
Endpoint specification is fundamental to clinical-trial statistics because the statistical method depends on what is measured. A binary endpoint, continuous measurement, count, time-to-event endpoint, and repeated-measures endpoint each require different assumptions and estimation strategies.
| Endpoint information | Registry record |
|---|---|
| Registered primary endpoints | None reported |
| Endpoint definitions | Not reported |
| Endpoint time frames | Not reported |
| Posted statistical analyses | None reported |
5. Statistical Methodology
Randomization and causal comparison
The randomized allocation is the principal statistical feature of AVF2107g. Randomization is designed to balance prognostic characteristics across treatment groups on average, thereby reducing systematic confounding of the treatment comparison.
The key distinction is between randomized treatment assignment and treatment actually received. An analysis based on randomized assignment generally preserves the causal comparison created by randomization, while an analysis restricted according to treatment received can introduce selection effects if treatment receipt is related to prognosis.
Why endpoint definition comes first
A statistical analysis cannot be specified completely until the endpoint is known. For example, a time-to-event endpoint would normally require a definition of the event, a time origin, censoring rules, and an analysis population. A continuous endpoint would instead require a defined measurement, summary statistic, and comparison model. These are not interchangeable choices.
The precise form of this treatment effect depends on the endpoint. It may be expressed as a difference, ratio, odds ratio, risk ratio, hazard ratio, mean difference, or another prespecified estimand.
Analysis population
The registry information does not report an analysis population definition. In a randomized treatment trial, the intention-to-treat principle is commonly used for primary efficacy comparisons because it retains participants according to their randomized assignment. Safety analyses often use an exposure-based population, but the specific AVF2107g analysis populations are not reported here.
Multiplicity
No multiplicity strategy is reported. If a trial evaluates multiple primary or secondary endpoints, multiple treatment comparisons, repeated interim looks, or numerous subgroup hypotheses, the statistical interpretation of individual P-values depends on the prespecified error-control strategy.
Interim analysis
No interim-analysis plan is reported. If interim efficacy analyses are performed, the nominal significance threshold at each look cannot automatically be treated as the final-analysis threshold because repeated examination of accumulating data can affect the overall type I error rate.
6. Statistical Methods Explained
Why does randomization matter statistically?
Randomization creates treatment groups through a chance-based allocation process rather than through clinical selection. This helps separate the effect of treatment assignment from systematic differences in patient characteristics. It does not guarantee identical groups in every baseline variable, and it does not eliminate problems caused by missing data, nonadherence, protocol deviations, or incomplete follow-up.
What does phase 3 tell us about the statistical role of the trial?
Phase 3 identifies the development phase of the study. In general, phase 3 randomized trials are designed to provide comparative evidence about treatment strategies in a larger confirmatory setting. The phase label itself does not specify the endpoint, effect measure, statistical model, or significance threshold.
Why must the endpoint be defined before choosing a statistical test?
The endpoint determines what constitutes an event or measurement and therefore determines the probability model used for analysis. For example, time-to-event data contain censoring information that ordinary comparisons of simple proportions do not capture. Without the endpoint definition, there is no defensible way to select one specific primary statistical test for AVF2107g.
What would a time-to-event analysis require?
If a study endpoint were time to an event, a conventional analysis could use Kaplan-Meier estimation to describe the event-time distribution and a log-rank or model-based comparison to compare randomized groups. A Cox proportional-hazards model could express the treatment comparison as a hazard ratio. The exact method would depend on the prespecified endpoint and statistical analysis plan.
Why is the hazard ratio not the same as a risk ratio?
A risk ratio compares probabilities over a specified time period. A hazard ratio instead compares modeled instantaneous event rates over time. These quantities answer different questions and cannot be substituted for one another merely because both are ratios.
Why does a P-value not measure treatment effect size?
A P-value describes the compatibility of observed data with a specified null hypothesis under the statistical model. It is affected by sample size and variability. An effect estimate and its confidence interval provide information about magnitude and precision that a P-value alone does not provide.
7. Planned Analysis
The ClinicalTrials.gov record identifies AVF2107g as a randomized phase 3 treatment study evaluating Avastin (bevacizumab) in combination with standard chemotherapy for colorectal cancer. However, the record information reported here does not contain registered primary endpoints or posted statistical analyses.
What would normally be analyzed?
A complete statistical analysis would begin by identifying the prespecified primary endpoint or endpoints, the estimand, the randomized comparison, the analysis population, and the method used to quantify uncertainty. The appropriate model would then follow from the endpoint structure.
Time-to-event endpoint
Typically analyzed with Kaplan-Meier methods and a treatment comparison such as a log-rank test, with a Cox model often used to estimate a hazard ratio.
Binary endpoint
Typically summarized as response or event proportions and compared using an appropriate risk, odds, or probability-based treatment effect with a confidence interval.
Continuous endpoint
Typically summarized using means, medians, or other prespecified measures and compared with an appropriate model or treatment-effect contrast.
Repeated measurements
Would generally require a longitudinal analysis that accounts for within-patient correlation and the timing of measurements.
8. What Can Be Inferred From the Trial Design?
The randomized design supports a treatment comparison, but design information alone does not establish the magnitude or direction of an outcome difference. A completed trial can have a well-defined randomized structure while still requiring the actual endpoint definitions and outcome data to quantify treatment effects.
| Question | What the registry establishes | Statistical implication |
|---|---|---|
| Was treatment allocation randomized? | Yes | A randomized treatment comparison was part of the study design. |
| What was the study phase? | Phase 3 | The study was conducted as a phase 3 treatment evaluation. |
| What was the condition? | Colorectal Cancer | The clinical population is defined at the condition level. |
| What intervention was listed? | Avastin (bevacizumab) (drug) | The intervention under evaluation was Avastin. |
| What was the primary purpose? | Treatment | The registry classifies the study as a treatment study. |
| How many participants were enrolled? | Not reported | A sample-size-based precision assessment cannot be made from the reported registry information. |
| What were the primary endpoints? | None reported | A specific primary statistical analysis cannot be identified from the registry information. |
9. Statistical Interpretation of a Randomized Phase 3 Design
Randomization primarily addresses comparability of treatment assignment. It does not by itself demonstrate efficacy. The observed outcomes must still be compared using an endpoint-specific statistical analysis.
An effect estimate describes the magnitude and direction of the observed treatment difference according to a defined estimand. Without a reported endpoint and estimate, the treatment effect for AVF2107g cannot be numerically characterized from the registry information.
A confidence interval quantifies statistical uncertainty around an estimated treatment effect under the specified statistical framework. Its interpretation depends on the effect measure, analysis model, and confidence level.
A P-value addresses a null-hypothesis testing question. It is not a measure of clinical importance, does not quantify the probability that a treatment works, and should not be interpreted without the associated effect estimate and analysis context.
10. Limitations and Interpretation Issues
- Endpoint information: the registry record information reported here contains no registered primary endpoints, so the primary outcome measure and its time frame cannot be identified.
- No posted statistical analyses: no statistical analyses are reported in the ClinicalTrials.gov statistical-analysis fields described here.
- Enrollment: enrollment is not reported in the registry information, preventing a direct assessment of sample-size-based statistical precision.
- Comparator details: the record identifies the study as randomized but does not provide the comparator regimen in the information reported here.
- Analysis populations: definitions of intention-to-treat, per-protocol, safety, or other analysis populations are not reported.
- Stratification: no randomization stratification factors are reported.
- Multiplicity: no multiplicity-adjustment strategy is reported, so no conclusions about familywise type I error control can be made from the registry information.
- Interim monitoring: no interim-analysis procedure is reported.
- Missing data: no imputation or missing-data strategy is reported.
- Blinding: the registry information reported here does not specify whether participants, investigators, outcome assessors, or analysts were blinded.
- Crossover: no crossover procedure is reported.
- Bayesian methods: no Bayesian analysis is reported.
11. Why This Trial Matters Statistically
AVF2107g is a useful statistical teaching case because its registry description contains the essential elements of a randomized treatment study while leaving the endpoint-level analysis unspecified. That distinction is important: a clinical-trial design tells us how treatment assignment was structured, whereas the endpoint and analysis plan determine how evidence about treatment effects is quantified.
| Concept | How it appears in AVF2107g |
|---|---|
| Randomization | The allocation is identified as randomized. |
| Phase 3 design | The study is classified as phase 3. |
| Treatment purpose | The primary purpose is classified as treatment. |
| Comparative treatment evaluation | The intervention is Avastin (bevacizumab) in combination with standard chemotherapy. |
| Endpoint specification | No registered primary endpoints are reported. |
| Effect estimation | No posted statistical estimates are reported. |
| Confidence intervals | No posted confidence intervals are reported. |
| Hypothesis testing | No posted P-values or formal statistical analyses are reported. |
| Sample-size interpretation | Enrollment is not reported. |
| Statistical design features | Stratification, multiplicity, interim analysis, missing-data methods, crossover, and Bayesian methods are not reported. |
12. A Practical Framework for Reading AVF2107g
A rigorous statistical reading of a randomized clinical trial proceeds in a defined order. First identify the population and treatment comparison. Then identify the primary estimand and endpoint. Next determine the analysis population, statistical model, uncertainty measure, and hypothesis-testing framework. Only after those elements are established should numerical treatment effects be interpreted.
Step 1 · Design
Confirm that treatment assignment was randomized and determine how the groups were constructed.
Step 2 · Endpoint
Identify exactly what was measured, how it was defined, and over what time frame.
Step 3 · Estimand
Define the treatment effect being estimated and the population to which it applies.
Step 4 · Model
Select the statistical method appropriate for the endpoint and its data structure.
Step 5 · Uncertainty
Interpret the treatment estimate together with its confidence interval and relevant assumptions.
Step 6 · Multiplicity
Determine whether multiple endpoints, treatment comparisons, or interim looks affect the error-control framework.
13. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The study design supports a randomized comparison of treatment strategies. The registry information reported here does not provide the primary endpoint, treatment-effect estimate, confidence interval, or P-value needed for an endpoint-level statistical conclusion.
Clinical interpretation
The registry identifies AVF2107g as a phase 3 treatment study of Avastin (bevacizumab) in combination with standard chemotherapy for colorectal cancer. Clinical benefit cannot be characterized from the design information alone.
14. What Is Missing From an Endpoint-Level Statistical Analysis?
A complete statistical analysis requires more than knowing that a trial was randomized and phase 3. At minimum, the analysis needs a defined outcome, the treatment comparison, the analysis population, an effect measure, and a method for quantifying uncertainty.
| Statistical component | Why it matters |
|---|---|
| Primary endpoint | Defines the principal outcome against which the treatment comparison is evaluated. |
| Endpoint definition | Determines exactly what constitutes an event, response, measurement, or failure. |
| Time frame | Defines when the endpoint is assessed and prevents ambiguity about follow-up. |
| Analysis population | Determines which participants contribute to the primary estimate. |
| Effect measure | Determines whether treatment effect is expressed as a difference, ratio, hazard ratio, or another quantity. |
| Confidence interval | Shows the statistical precision associated with the effect estimate. |
| Hypothesis test | Defines the null hypothesis and the statistical evidence threshold. |
| Multiplicity plan | Determines how multiple statistical questions affect type I error control. |
| Missing-data strategy | Determines how incomplete observations are handled in the analysis. |
15. Trial History
AVF2107g begins
The registry lists the study start date as 2000-09 and identifies the study as a phase 3 randomized treatment study in colorectal cancer.
Study completed
The ClinicalTrials.gov record identifies the study status as completed.
16. Sponsor and Study Classification
| Registry field | AVF2107g |
|---|---|
| Lead sponsor | Genentech, Inc. |
| Sponsor type | Industry |
| Study phase | Phase 3 |
| Primary purpose | Treatment |
| Allocation | Randomized |
| Condition | Colorectal Cancer |
| Intervention | Avastin (bevacizumab) (drug) |
Sponsor type and study phase are descriptive characteristics of the trial rather than statistical evidence about treatment efficacy. Statistical conclusions should be based on the prespecified randomized comparison, endpoint data, analysis methods, and uncertainty around the resulting estimates.
17. Statistical Takeaways
Each step contributes something different. Randomization establishes the structure of the treatment comparison; the endpoint defines what is measured; the estimand defines the treatment effect; the model produces an estimate; and the confidence interval describes its statistical precision.
For AVF2107g, the registry establishes the first part of this sequence: it was a randomized phase 3 treatment study evaluating Avastin (bevacizumab) in combination with standard chemotherapy for colorectal cancer. The registry information reported here does not establish the subsequent endpoint-specific statistical results.
18. Sources
- ClinicalTrials.gov: NCT00109070 — AVF2107g.
Continue through Clinical Biostats
Explore additional clinical trial results, statistical tutorials, and analysis resources.
19. Record Summary
AVF2107g was a completed randomized phase 3 treatment study evaluating Avastin (bevacizumab) in combination with standard chemotherapy for colorectal cancer. The registry identifies Genentech, Inc. as the lead industry sponsor and lists the study start as 2000-09. From a statistical perspective, the randomized design provides the framework for a comparative treatment analysis, but the endpoint-specific interpretation requires the primary endpoint definitions, analysis populations, statistical methods, effect estimates, and uncertainty measures. Those statistical-analysis results are not posted in the ClinicalTrials.gov information reported here.